Den här hemsidan kräver JavaScript för att fungera tillfredsställande. Vänligen ändra dina inställningar eller använd en annan webläsare för att fortsätta.       

Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

Unit for Hours:H

Unit for Minutes: M

Filter redirection page URL: /content/cf-pharma/health-hcpportal/se_SE/hcp/home/events.html

Login overlay needed?:

Filter Tags:Terapiområde

Filter Tags values when filtered by all Tags:Alla terapiområden

OutofBox filter category name:Typ

Filter Reset all button text:Återställ

Filter Apply button text:Apply

Events registration success message: Registration successfull

Events registration failure message: Registration failure

Events un-registration success message: Un-Registration successfull

Events un-registration failure message: Un-Registration failure

Reset all default value: false

Tag Requirements value: all

Show More Naivagation Values: 10|25|50

Previous Text label: Tidigare

Next Text label: Nästa

Show Text label: Visa:

Seats left Text: Spaces left

No Seats left Text: No spaces left

Text Area Blank copy in Email Template:Ej ifyllt

  

Month Names:Januari,Februari,Mars,April,Maj,Juni,Juli,Augusti,September,Oktober,November,December

  

Month Names Short:Jan,Feb,Mar,Apr,Maj,Jun,Jul,Aug,Sep,Okt,Nov,Dec

  

Day Names:Söndag,Måndag,Tisdag,Onsdag,Torsdag,Fredag,Lördag

  

Day Names Short:Sön,Mån,Tis,Ons,Tor,Fre,Lör

  

Day Names Min:Sö,Må,Ti,On,To,Fr,Lö

  

Date Format:dag/månad/år

  • ASYEVE0001=Event Registration-Portal
  • ASYEVE0002=Watched General Video
  • ASYEVE0003=Watched Virtual Rep Video
  • ASYEVE0004=Watched Patient Video
  • ASYEVE0005=Watched Expert Video
  • ASYEVE0006=Watched Webcast
  • ASYEVE0007=Downloaded Content-Portal
  • ASYEVE0008=Clicked to App Store
  • ASYEVE0009=Watched Learning Module Video
  • ASYEVE0010=eMail Sent
  • ASYEVE0011=eMail Read
  • ASYEVE0012=eMail Clicked
  • ASYEVE0013=Shared a Link
  • ASYEVE0014=Rep Request
  • ASYEVE0015=Joined health.gsk
  • ASYEVE0016=email Not Sent
  • ASYEVE0017=Email Not Sent
  • ASYEVE0018=Email Not Sent
  • ASYEVE0037=IJSFAID is not available
  • ASYEVE0038=EMAIL ID and IJSFAID is not available
  • ASYEVE0039=The user is opted out
  • ASYEVE0040=Scope IDs are different

March 2018

CROI 2018—DTG versus LPV/r in second line (DAWNING): Outcomes by WHO-recommended NRTI Backbone 1

Effectiveness of dolutegravir-based ART vs WHO-recommended lopinavir/ritonavir-based ART as second-line treatment

  • Non-inferiority study comparing DTG + 2 NRTIs with a WHO-recommended regimen of LPV/r + 2 NRTIs in HIV-1-infected adults failing first-line therapy (HIV-1 RNA ≥400 copies [c]/mL) of NNRTI + 2 NRTIs
  • Week 24: DTG + 2 NRTIs was superior to lopinavir/ritonavir (LPV/r) + 2 NRTIs, with 82% (n=257) and 69% (n=215) of subjects achieving HIV-1 RNA <50 c/mL, respectively (P<0.001)
  • Difference primarily driven by lower rates of Snapshot virological non-response in the DTG group
  • Response rates were higher within each arm among the 56% (n=347) of subjects receiving WHO-recommended second-line NRTIs; however, response rates were higher with DTG- vs LPV/r-based regimens regardless of WHO-recommended NRTI use
  • The overall safety profile of DTG + 2 NRTIs was favourable compared with LPV/r + 2 NRTIs
  • Access DAWNING data previously presented at IAS regarding protocol-defined virological failure favouring the DTG arm here

Access the full abstract here.

 

“…regardless of WHO-recommended NRTI use, response rates were higher with DTG versus LPV/r-based regimens..”

 

Reference:

  1. DTG versus LPV/r in second line (DAWNING): Outcomes by WHO-recommended NRTI Backbone. Presented at: Conference on Retroviruses and Opportunistic Infections; March 4-7, 2018; Boston, MA.